3 healthcare stocks with stable dividend growth
Investing in healthcare stocks that offer steady dividend growth is an attractive strategy for investors seeking reliable income. Let's take a look at three major companies in this sector.
Today, we'll be talking about Amgen $AMGN+0.5%, Merck $MRK+0.5%, and AbbVie $ABBV+2.1%. These companies not only pay regular dividends, but also have strong financial stability and innovative products that keep them at the top of the market.
Amgen
Amgen
AMGNAmgen is one of the largest biotechnology companies in the world. Its core business is the development and production of human therapeutics aimed at treating serious diseases such as autoimmune diseases, cancer and osteoporosis. Amgen supplies its products to a wide range of healthcare facilities, from hospitals to pharmacies.
Amgen's most important products include Enbrelwhich is used in the treatment of rheumatoid arthritis, and Prolia, a drug for osteoporosis. These products provide stable revenues and contribute to the company's growth. Amgen boasts a 14-year history of paying dividends, which it has increased for 13 years in a row. The current quarterly dividend is $2.25 per share, representing an annual yield of about 2.83%.
In the last twelve months, the company posted revenue of $29.5 billion and net income of $3.76 billion. This strong financial performance is the result of effective cost management and the continued development of new therapeutic options. Amgen is also investing in research and development to maintain its competitive advantage and bring new innovative products to market.
Merck
Merck & Co.
MRKMerck & Co. is a global pharmaceutical company with a broad portfolio of drugs and vaccines, covering areas such as oncology, cardiovascular disease, immunology and infectious diseases. In addition to human medicines, Merck also operates a division Animal Healthwhich specialises in veterinary pharmaceuticals and vaccines.
One of the company's most important products is Keytrudaan immunotherapy drug used in the treatment of various cancers. This drug has become an important source of revenue and contributes significantly to the company's financial health. Merck has increased its dividend for 13 consecutive years, with a current quarterly dividend of $0.77 per share, for an annual yield of approximately 2.32%.
Merck stock is up more than 9% this year, and the company has beaten earnings and revenue expectations for 11 consecutive quarters. In the past year, it generated $61.4 billion in revenue and $2.3 billion in net income. This growth is supported by the success of key products and a strong position in the global pharmaceutical market.
AbbVie
AbbVie
ABBVAbbVie is a pharmaceutical company that focuses on the development and manufacture of drugs in the areas of immunology, oncology, neuroscience and eye care. Its best known product, Humira, is widely used in the treatment of autoimmune diseases and is one of the best-selling drugs in the world. In addition to Humira, AbbVie also offers Imbruvicaa drug used in the treatment of specific types of cancer.
AbbVie has a history of 11 years of dividend increases, with a current quarterly dividend of $1.55 per share, for an annual yield of about 3.59%. In the most recent year, the company reported revenue of $54.4 billion and net income of $5.99 billion. These results underscore its strong financial position and ability to generate stable earnings.
The company is investing heavily in research and development to expand its product portfolio and maintain its market leadership. Recent acquisitions and partnerships, including the purchase of Allergan, point to its strategy to expand its reach in aesthetic medicine and other high-growth markets.
Disclaimer: There is plenty of inspiration to be found on Bulios, but stock selection and portfolio construction is up to you, so always conduct thorough self-analysis.
Source: Yahoo Finance, CNBC.